Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2635
http://purl.obolibrary.org/obo/NCIT_C2635
|
|---|---|
| Preferred Name | Pirfenidone |
| Definitions |
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI04) |
|---|---|
| prefLabel | Pirfenidone
|
| label | Pirfenidone
|
| PDQ_Closed_Trial_Search_ID | 38334
|
| code | C2635
|
| prefixIRI | NCIT:C2635
|
| in_subset |
See more
See less
|
| Preferred_Name | Pirfenidone
|
| FDA_UNII_Code | D7NLD2JX7U
|
| Contributing_Source | FDA
|
| Chemical_Formula | C12H11NO
|
| Maps_To | Pirfenidone
|
| CAS_Registry | 53179-13-8
|
| NCI_Drug_Dictionary_ID | 38334
|
| Legacy Concept Name | Pirfenidone
|
| type | |
| ALT_DEFINITION | A substance that is being studied in the prevention and treatment of scar tissue caused by radiation therapy. It belongs to the family of drugs called anti-inflammatory agents.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38334
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0298067
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |